Shares of Cytokinetics (NASDAQ: CYTK) climbed 6.8% in early trading Thursday after the FDA approved its heart drug MYQORZO, marking a significant milestone for the biopharmaceutical company. The gains came despite ongoing scrutiny over insider stock sales and a reported probe into trading activity by company executives.
The approval positions MYQORZO as a potential blockbuster treatment for hypertrophic cardiomyopathy, a condition affecting an estimated 1 in 500 Americans. Analysts project peak annual sales could exceed $2 billion if the drug gains broad adoption.
‘This FDA green light validates years of research investment,’ said a biotech analyst at a major investment bank who requested anonymity due to firm policy. ‘However, the timing of executive stock sales prior to the approval raises legitimate questions about transparency.’
SEC filings show three Cytokinetics executives sold approximately $15 million in shares during the 60-day period preceding the FDA decision. While company representatives stated these were pre-scheduled transactions under Rule 10b5-1 plans, sources familiar with the matter say regulators are examining whether all disclosure requirements were met.
The dual narrative of scientific achievement and corporate governance concerns creates uncertainty for investors. Some institutional holders have reportedly increased their positions, betting on the drug’s commercial potential, while others remain cautious until regulatory inquiries conclude.
Market observers suggest the coming weeks will prove critical as investors assess MYQORZO’s launch trajectory and whether the insider trading probe expands. The company faces stiff competition from Bristol-Myers Squibb’s mavacamten, approved last year for the same indication.